CNMD Strangle Strategy

CNMD (CONMED Corporation), in the Healthcare sector, (Medical - Devices industry), listed on NYSE.

CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system.

CNMD (CONMED Corporation) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $1.08B, a trailing P/E of 20.05, a beta of 0.92 versus the broader market, a 52-week range of 31.44-56.64, average daily share volume of 485K, a public-listing history dating back to 1987, approximately 4K full-time employees. These structural characteristics shape how CNMD stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.92 places CNMD roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. CNMD pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.

What is a strangle on CNMD?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current CNMD snapshot

As of June 29, 2026, spot at $34.33, ATM IV 69.40%, IV rank 19.50%, expected move 19.90%. The strangle on CNMD below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.

Why this strangle structure on CNMD specifically: CNMD IV at 69.40% is on the cheap side of its 1-year range, which favors premium-buying structures like a CNMD strangle, with a market-implied 1-standard-deviation move of approximately 19.90% (roughly $6.83 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CNMD expiries trade a higher absolute premium for lower per-day decay. Position sizing on CNMD should anchor to the underlying notional of $34.33 per share and to the trader's directional view on CNMD stock.

CNMD strangle setup

The CNMD strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CNMD near $34.33, the first option leg uses a $36.05 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CNMD chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CNMD shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$36.05	N/A
Buy 1	Put	$32.61	N/A

CNMD strangle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

CNMD strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on CNMD. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on CNMD

Strangles on CNMD are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CNMD chain.

CNMD thesis for this strangle

The market-implied 1-standard-deviation range for CNMD extends from approximately $27.50 on the downside to $41.16 on the upside. A CNMD long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current CNMD IV rank near 19.50% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CNMD at 69.40%. As a Healthcare name, CNMD options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CNMD-specific events.

CNMD strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CNMD positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CNMD alongside the broader basket even when CNMD-specific fundamentals are unchanged. Always rebuild the position from current CNMD chain quotes before placing a trade.

Frequently asked questions

What is a strangle on CNMD?: A strangle on CNMD is the strangle strategy applied to CNMD (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With CNMD stock trading near $34.33, the strikes shown on this page are snapped to the nearest listed CNMD chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are CNMD strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the CNMD strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 69.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a CNMD strangle?: The breakeven for the CNMD strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CNMD market-implied 1-standard-deviation expected move is approximately 19.90%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on CNMD?: Strangles on CNMD are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CNMD chain.
How does current CNMD implied volatility affect this strangle?: CNMD ATM IV is at 69.40% with IV rank near 19.50%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.